Needham analyst Chad Messer raised his price target on Sarepta to $204 and kept his Buy rating after the company's R&D day, which showcased an "impressive 21 developmental programs around precision genetic medicine for Duchenne's Muscular Dystrophy and other muscular dystrohpies." Messer adds that the highlight of the event was the gene therapy data, with the company also releasing data on 3 DMD patients showing "significant functional improvement" 90 days after the injections. The analyst notes that the steep rise in his price target is appropriate given the company's visibility on it future profitability.